ATE526029T1 - Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung - Google Patents

Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung

Info

Publication number
ATE526029T1
ATE526029T1 AT02760663T AT02760663T ATE526029T1 AT E526029 T1 ATE526029 T1 AT E526029T1 AT 02760663 T AT02760663 T AT 02760663T AT 02760663 T AT02760663 T AT 02760663T AT E526029 T1 ATE526029 T1 AT E526029T1
Authority
AT
Austria
Prior art keywords
histone deacetylase
deacetylase inhibitor
assessing
medical use
tumoral effect
Prior art date
Application number
AT02760663T
Other languages
English (en)
Inventor
Yuka Sasakawa
Yoshinori Naoe
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE526029T1 publication Critical patent/ATE526029T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02760663T 2001-08-21 2002-08-20 Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung ATE526029T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001250846 2001-08-21
PCT/JP2002/008355 WO2003015810A1 (en) 2001-08-21 2002-08-20 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof

Publications (1)

Publication Number Publication Date
ATE526029T1 true ATE526029T1 (de) 2011-10-15

Family

ID=19079582

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02760663T ATE526029T1 (de) 2001-08-21 2002-08-20 Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung

Country Status (14)

Country Link
US (1) US8470783B2 (de)
EP (1) EP1426054B1 (de)
JP (1) JP4238728B2 (de)
AT (1) ATE526029T1 (de)
CA (1) CA2457043A1 (de)
DK (1) DK1426054T3 (de)
ES (1) ES2371630T3 (de)
HU (1) HU229521B1 (de)
MX (1) MXPA04001612A (de)
NO (1) NO331682B1 (de)
PL (1) PL210794B1 (de)
PT (1) PT1426054E (de)
RU (1) RU2298414C2 (de)
WO (1) WO2003015810A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492596A1 (de) * 2002-04-05 2005-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptid zur behandlung von nierenkrebs
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2004074478A1 (ja) * 2003-02-19 2004-09-02 Astellas Pharma Inc. ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1638541B1 (de) 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutisches mittel für ein weichteilsarkom
DE602004027824D1 (de) * 2003-09-25 2010-08-05 Astellas Pharma Inc Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
WO2005058298A2 (en) * 2003-12-10 2005-06-30 Wisconsin Alumni Research Foundation Fk228 analogs and their use as hdac-inhibitors
EP1697538A1 (de) * 2003-12-18 2006-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Verfahren zur identifizierung von histondeacetylase-inhibitoren
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
KR101167601B1 (ko) * 2004-02-25 2012-07-27 아스텔라스세이야쿠 가부시키가이샤 항종양제
JP2006000113A (ja) * 2004-05-20 2006-01-05 Masatomo Sakurai 漢方医療の診断に用いる遺伝子およびその利用方法
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
WO2006094068A2 (en) 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Hdac inhibitors that promote brm expression and brm related diagnostics
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
SI1901729T1 (sl) 2005-05-13 2012-05-31 Topotarget Uk Ltd Farmacevtske formulacije HDAC inhibitorjev
CA2615105A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2006283677A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
CA2627923C (en) 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
CA2630216A1 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the hdac inhibitor fk228
US9539303B2 (en) * 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
PT2099442E (pt) 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
EP2102230A2 (de) 2006-12-29 2009-09-23 Gloucester Pharmaceuticals, Inc. Reinigung von romidepsin
CN103497238A (zh) * 2006-12-29 2014-01-08 细胞基因公司 制备Romidepsin
US7838234B2 (en) 2007-01-30 2010-11-23 Pharmacyclics, Inc. Methods for determining cancer resistance to histone deacetylase inhibitors
CN101868446A (zh) 2007-09-25 2010-10-20 托波塔吉特英国有限公司 某些异羟肟酸化合物的合成方法
CN103108648A (zh) 2010-07-12 2013-05-15 细胞基因公司 罗米地辛固体形式及其用途
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
NZ503061A (en) * 1997-09-02 2001-08-31 Japan Energy Corp Cyclic tetrapeptide derivatives and use as anti-cancer agents
US6252058B1 (en) * 1997-11-05 2001-06-26 Timothy C. Thompson Sequences for targeting metastatic cells
JPH11335375A (ja) 1998-05-20 1999-12-07 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
BR0014254A (pt) 1999-09-08 2002-08-27 Sloan Kettering Inst Cancer Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos
EP1246839B1 (de) 1999-12-08 2004-06-16 Xcyte Therapies, Inc. Depsipeptide und deren analoge zur verwendung als immunosuppressiva
CA2317003A1 (en) 2000-02-28 2001-08-28 Hidenori Nakajima Gene expression potentiator
JP2001348340A (ja) * 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
ATE425177T1 (de) 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
EP1492596A1 (de) 2002-04-05 2005-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptid zur behandlung von nierenkrebs
EP1638541B1 (de) 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutisches mittel für ein weichteilsarkom
DE602004027824D1 (de) 2003-09-25 2010-08-05 Astellas Pharma Inc Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent

Also Published As

Publication number Publication date
NO20040731L (no) 2004-04-20
CA2457043A1 (en) 2003-02-27
EP1426054A1 (de) 2004-06-09
WO2003015810A1 (en) 2003-02-27
NO331682B1 (no) 2012-02-20
US20050191713A1 (en) 2005-09-01
EP1426054A4 (de) 2006-09-13
PL210794B1 (pl) 2012-03-30
HUP0400668A3 (en) 2012-09-28
ES2371630T3 (es) 2012-01-05
JP4238728B2 (ja) 2009-03-18
RU2298414C2 (ru) 2007-05-10
RU2004108137A (ru) 2005-05-10
HUP0400668A2 (hu) 2005-01-28
EP1426054B1 (de) 2011-09-28
MXPA04001612A (es) 2004-07-08
PL368708A1 (en) 2005-04-04
US8470783B2 (en) 2013-06-25
HU229521B1 (hu) 2014-01-28
JPWO2003015810A1 (ja) 2004-12-02
PT1426054E (pt) 2011-12-06
DK1426054T3 (da) 2011-12-12

Similar Documents

Publication Publication Date Title
EP1426054A4 (de) Medizinische verwendung eines histon-deacetylase-hemmers und verfahren zur beurteilung seiner antitumoralen wirkung
ATE511655T1 (de) Verfahren zur auswertung eines myelounterdrückungszustands
ATE442592T1 (de) Detektion und/oder beobachtung von synuclein- assoziierten krankheiten
NZ593388A (en) Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
TR200201246T2 (tr) Hidroksieikosatetraenoik asit türevlerini ihtiva eden bileşimler ve göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri
ATE290375T1 (de) Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen
DE60329274D1 (de) Kontrastmittel und verfahren zum imaging von naaldase oder psma
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
TW200735890A (en) Compositions and methods for increasing insulin sensitivity
BR9916785A (pt) Tratamento de asma com inibidores mek
WO2000062070A3 (en) Tissue inhibitor of matrix metalloproteinases type-1 (timp-1) as a cancer marker
DE602005024597D1 (de) Therapeutische mittel zum targeting des ncca-atp-kanals und verwendungsverfahren dafür
IL142824A0 (en) Lipoic acid derivatives and their use in treatment of disease
BRPI0508451A (pt) método de tratamento de linfoma não-hodgkin em um mamìfero, usos de uma combinação de cci-779 e rituximab e de uma combinação de um inibidor de mtor e rituximab, produtos contendo cci-779 e rituximab e um inibidor mtor e rituximab, embalagem farmacêutica, e, composição farmacêutica
WO2007100728A3 (en) Mannose derivatives for killing tumor cells
DE602005024704D1 (de) Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür
ATE557087T1 (de) Verfahren und kit zum nachweis von sklerose verursachenden proliferativen erkrankungen und/oder heilmittel gegen sklerose verursachende proliferative erkrankungen sowie verfahren und kit zur identifizierung einer bei der vorbeugung und/oder behandlung von sklerose verursachenden proliferativen erkrankungen wirksamen substanz
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
EA201000630A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
GB0305153D0 (en) Identification of therapeutic compounds
BRPI0408238A (pt) anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1426054

Country of ref document: EP